Filing Flows › Regenxbio (RGNX) › Q2 2025
Regenxbio (RGNX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Regenxbio (RGNX) reported revenue of $21.4M for the second quarter 2025 (Q2 2025), -4% from a year earlier and -76% from the quarter before. Operating margin was -296.3%, net loss $70.9M (331.8% of revenue).
Regenxbio, Q2 2025: revenue $21.4M (-4% year over year), operating margin -296.3%, net loss $70.9M, operating cash flow −$49.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.4M | -76% | -4% |
| Operating profit | −$63.3M | -622% | — |
| Net earnings | −$70.9M | -1265% | — |
| Operating cash flow | −$49.3M | -247% | — |
What changed
Revenue was $21.4M in Q2 2025, down 4% year over year and down 76% from the previous quarter. License and Service was the largest line at 86% of revenue. License and Service lost $3.4M year over year (down 15%), 361% of the total change.
Operating costs exceeded revenue by $63.3M, an operating margin of -296.3%. Total costs grew 8% against a revenue fall of 4%. The fastest-growing cost line was Research & development (+22%). The quarter ended with a net loss of $70.9M, after a profit of $6.1M the previous quarter.
Operating cash flow was −$49.3M. Non-cash charges added back $3.9M of depreciation and amortization and $8.7M of share-based compensation. Working capital and other items added $9.0M. Capital expenditures of $391K exceeded it, leaving free cash flow of −$49.7M.
Questions
What was Regenxbio's revenue in the second quarter 2025?
Regenxbio (RGNX) reported revenue of $21.4M for the second quarter 2025 (Q2 2025), -4% from a year earlier and -76% from the quarter before.
Was Regenxbio profitable in the second quarter 2025?
Operating loss was $63.3M (-296.3% of revenue) and net loss $70.9M.
Source: Regenxbio 10-Q on SEC EDGAR.